{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:12Z","timestamp":1789972092399,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.joms.2010.05.043","type":"journal-article","created":{"date-parts":[[2010,8,20]],"date-time":"2010-08-20T06:39:37Z","timestamp":1282286377000},"page":"2241-2247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Serologic Bone Markers for Predicting Development of Osteonecrosis of the Jaw in Patients Receiving Bisphosphonates"],"prefix":"10.1016","volume":"68","author":[{"given":"Towy Sorel","family":"Lazarovici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit","family":"Mesilaty-Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Vered","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kanety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navot","family":"Givol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Yahalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Taicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Yarom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2010.05.043_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01623652","article-title":"Rationale for the use of alendronate in osteoporosis","volume":"5","author":"Kanis","year":"1995","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2010.05.043_bib2","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q","article-title":"Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer","volume":"74","author":"Glover","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.joms.2010.05.043_bib3","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1359\/jbmr.1999.14.9.1557","article-title":"A dose-finding study of zoledronate in hypercalcemic cancer patients","volume":"14","author":"Body","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"Suppl","key":"10.1016\/j.joms.2010.05.043_bib4","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.joms.2010.05.043_bib5","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.joms.2010.05.043_bib6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0278-2391(03)00328-8","article-title":"Osteonecrosis of the jaws associated with cancer chemotherapy","volume":"61","author":"Wang","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib9","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteoporosis) of the jaws: Risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib10","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper","volume":"136","author":"Migliorati","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.joms.2010.05.043_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib12","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00198-007-0384-2","article-title":"Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome","volume":"18","author":"Yarom","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2010.05.043_bib13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.joms.2008.11.015","article-title":"Bisphosphonate-related osteonecrosis of the jaws: A single-center study of 101 patients","volume":"67","author":"Lazarovici","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.joms.2009.09.017","article-title":"Bisphosphonate-related osteonecrosis of the jaws associated with dental implants","volume":"68","author":"Lazarovici","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","article-title":"Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?","volume":"63","author":"Hellstein","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2010.05.043_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hon.819","article-title":"Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells","volume":"25","author":"Oteri","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.joms.2010.05.043_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF01623388","article-title":"New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis","volume":"6","author":"Guerrero","year":"1996","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2010.05.043_bib19","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2010.05.043_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1742-1241.2008.01911.x","article-title":"Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: A consensus document of the Belgian Bone Club","volume":"63","author":"Bergmann","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.joms.2010.05.043_bib21","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-008-0660-9","article-title":"Biochemical markers of bone turnover: Potential use in the investigation and management of postmenopausal osteoporosis","volume":"19","author":"Szulc","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2010.05.043_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s002230020042","article-title":"Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I","volume":"69","author":"Reginster","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.joms.2010.05.043_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S8756-3282(00)00272-6","article-title":"Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women","volume":"26","author":"Bjarnason","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.joms.2010.05.043_bib24","first-page":"1904","article-title":"The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation","volume":"82","author":"Rosen","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2010.05.043_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00005830","article-title":"Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy","volume":"66","author":"Rosen","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.joms.2010.05.043_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbspin.2006.05.011","article-title":"How long should patients take medications for postmenopausal osteoporosis?","volume":"74","author":"Briot","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.joms.2010.05.043_bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1677\/joe.1.06057","article-title":"Parathyroid hormone: Past and present","volume":"187","author":"Potts","year":"2005","journal-title":"J Endocrinol"},{"key":"10.1016\/j.joms.2010.05.043_bib28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.dinthera.2005.03.003","article-title":"Potential use of biochemical markers of bone turnover for assessing the effect of calcium supplementation and predicting fracture risk","volume":"27","author":"Weisman","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.joms.2010.05.043_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jcms.2007.06.008","article-title":"Bis-phossy jaws\u2014High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw","volume":"36","author":"Abu-Id","year":"2008","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib30","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib31","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"Position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib33","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","article-title":"Serum CrossLaps One Step ELISA: First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen","volume":"44","author":"Rosenquist","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.joms.2010.05.043_bib34","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/clinchem\/41.11.1560","article-title":"Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum","volume":"41","author":"Gomez","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.joms.2010.05.043_bib35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1258\/0004563021902044","article-title":"Comparison of intact and \u201cwhole molecule\u201d parathyroid hormone assays in patients with histologically confirmed post-renal transplant osteodystrophy","volume":"39","author":"Godber","year":"2002","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.joms.2010.05.043_bib36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cca.2009.08.020","article-title":"Bone turnover markers in Spanish postmenopausal women: The Camargo cohort study","volume":"409","author":"Mart\u00ednez","year":"2009","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.joms.2010.05.043_bib37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1447-0756.2008.00868.x","article-title":"Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women","volume":"35","author":"Trento","year":"2009","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.joms.2010.05.043_bib38","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.joms.2008.01.054","article-title":"Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"66","author":"Khosla","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib39","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.oraloncology.2008.01.012","article-title":"Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates","volume":"44","author":"Bagan","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.joms.2010.05.043_bib40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.tripleo.2008.01.033","article-title":"Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws","volume":"106","author":"Lehrer","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.joms.2010.05.043_bib41","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.joms.2009.04.067","article-title":"Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Kwon","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib42","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/annonc\/mdl045","article-title":"Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?","volume":"17","author":"Ardine","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2010.05.043_bib43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure: Predicting risk of osteonecrosis of the jaw with oral bisphosphonate Exposure (PROBE) Investigators","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2010.05.043_bib44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies","volume":"44","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.joms.2010.05.043_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14219\/jada.archive.2009.0019","article-title":"Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw","volume":"140","author":"Sedghizadeh","year":"2009","journal-title":"J Am Dent Assoc"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239110005872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239110005872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:34:48Z","timestamp":1759509288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239110005872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0278239110005872"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2010.05.043","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serologic Bone Markers for Predicting Development of Osteonecrosis of the Jaw in Patients Receiving Bisphosphonates","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2010.05.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}